A pathway towards cures for Parkinson's and cancer

November 06, 2002

Researchers studying the Hedgehog signaling pathway have identified small molecules that could form the foundations of exciting new treatments for Parkinson's disease and certain cancers.

New research published in Journal of Biology - the open access journal for exceptional research - has identified small molecules that are able to stimulate or block the Hedgehog signalling pathway, which is essential to the development, maintenance and repair of cells in the human body. The potential of these molecules to be used as drugs to treat both degenerative diseases and cancer is exciting as their small size may allow these molecules to enter all parts of the body and cross the blood brain barrier, eliminating the need for injections of therapeutics directly into the target site.

The Hedgehog signaling pathway is crucial to the development of healthy animals as well as the maintenance and repair of adult cells. Hedgehog genes were first identified in the fruitfly, and were so called because fly embryos with a defect in this gene were covered in bristles. The central role of the Hedgehog signalling pathway in the regulation of the growth and division of specific types of cells makes it of great interest to researchers investigating diseases like Parkinson's that are characterised by a lack of particular cells as the central nervous system degenerates. Finding drugs that can stimulate the Hedgehog signaling pathway and lead to the production of new cells could potentially cure this disease. It is also hoped that by developing drugs that block the Hedgehog signalling pathway researchers will be able to induce the regression of tumours in patients with certain cancers that depend on this pathway (specifically, basal cell carcinoma and medulloblastoma).

Recent research has shown the Hedgehog protein can itself reduce the behavioural impairments and neuronal loss that occur in animal models of the Parkinson's disease suggesting that manipulating this pathway may well deliver new treatment. One major drawback of using the Hedgehog protein to manipulate the signaling pathway is that, because of it large size, it has to be administered by direct injection into the brain.

In the Journal of Biology article, a team of researchers led by Jeffrey A Porter of the biotechnology company, Curis Inc, of Cambridge Massachusetts, and including colleagues from Columbia University in New York, report their screen of around 140,000 synthetic molecules for the ability to stimulate or inhibit the Hedgehog signalling pathway. One of the molecules was studied further by creating around 300 chemical derivatives. Using this method the researchers were able to identify a range of active molecules that could have exciting therapeutic benefits.

Porter and colleagues then went on to characterise the small synthetic molecules to find out how they worked in living organisms, hopeful that this would give them further understanding of the Hedgehog signalling pathway. They found their small molecules were interacting with a poorly understood protein that is found on the surface of developing cells. This protein, called Smoothened, helps cells respond to the Hedgehog protein.

The interaction of the Smoothened protein with the synthetic small molecules suggests that the Hedgehog signalling pathway may involve similar small molecules to those synthesised in this study.

The authors conclude, "As a drug a Hedgehog agonist [one of the new molecules they have identified] would represent an attractive alternative to an expensive Hedgehog protein therapeutic."
-end-
This article will be published online and made available free of charge on Wednesday November 6, in line with the publisher's policy of providing immediate open access to original research: http://jbiol.com/1/2/10

The second issue of Journal of Biology will also include minireview and research news articles that will also be made freely available from http://jbiol.com, and which will be added to the press site ahead of publication.

Journal of Biology (http://jbiol.com) is a new international journal, published by BioMed Central, which provides immediate open access to research articles of exceptional interest. It will only publish research articles of the highest standard, similar to those published by Nature, Science or Cell. While these journals restrict access to only those who pay for a subscription, all research articles published in Journal of Biology will be permanently available free of charge and without restrictions, ensuring the widest possible dissemination of the work.

Contact details:

Journal of Biology
Editor Dr Theodora Bloom
E-mail editorial@jbiol.com
Telephone 44-207-323-0323
Facsimile 44-207-631-9961

Author Dr Jeffery A Porter, Curis, Inc.,
E-mail: jporter@curis.com
Telephone 617-503-6568
Facsimile 617-503-6501

http://jbiol.com/press/

Journal of Biology
Editor in Chief: Martin Raff
Website: http://jbiol.com
Publisher: BioMed Central
Format: online and print

BioMed Central

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.